# Vantage Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vantage-oncology

- Industry: Healthcare
- Headquarters: Manhattan Beach, US
- Website: www.vantageoncology.com
- Total disclosed funding: $43M
- Latest round: Series C (Aug 28, 2006)
- Investors on record: 4

## About

Vantage Oncology provides advanced radiation therapy solutions aimed at improving patient outcomes in cancer treatment through innovative technology and equipment.Founded in 2002 in Manhattan Beach, US, Vantage Oncology specializes in radiation therapy solutions tailored for cancer treatment. The company has undergone significant growth, securing a total of USD 22.50 mn through its funding rounds, culminating in its latest funding round, Series D. The founders, Leslie Botnick and Michael Fiore, are known for their expertise in oncology and healthcare technology. Vantage Oncology has successfully completed 8 deals, establishing its presence in the oncology market.Vantage Oncology specializes in providing advanced radiation therapy solutions aimed at improving patient outcomes in cancer treatment. Their primary product offerings include state-of-the-art linear accelerators, treatment planning software, and integrated oncology management systems. These products are designed to enhance the precision and effectiveness of radiation therapy, catering to a wide range of cancer types. Their target end users include hospitals, cancer treatment centers, and outpatient facilities, which rely on Vantage Oncology's technology to deliver effective care. The company markets its solutions extensively in regions such as North America, Europe, and select Asia-Pacific countries, ensuring that healthcare providers have access to the latest advancements in oncology technology.Vantage Oncology generates revenue primarily through direct sales of their radiation therapy equipment and software solutions to healthcare providers. Transactions typically occur on a B2B basis, with hospitals and treatment centers purchasing or leasing equipment through structured agreements. The company may offer different pricing plans based on the complexity and scale of the solutions, including options for maintenance and support services. These arrangements can include partnerships with healthcare institutions, where Vantage Oncology provides ongoing support and updates for their systems. Their flagship products, integral to their revenue model, include proprietary treatment planning software, which plays a crucial role in optimizing patient treatment pathways.Vantage Oncology plans to leverage its recent funding from Granite Growth Health Partners to enhance its product offerings and expand its market reach. The company aims to develop new radiation therapy technologies and intends to launch these innovative solutions in the upcoming year. Additionally, Vantage Oncology is targeting expansion into new geographic regions, including Europe and select countries in the Asia-Pacific area, by the end of 2024. This strategy is designed to enhance their competitive position and increase their share in the global oncology market, utilizing the funding to support research, development, and marketing initiatives.

## Funding rounds

- Series C, Aug 28, 2006, $6M — CCP Equity Partners, New Enterprise Associates, Versant Ventures, Salix Ventures
- Series C, May 9, 2005, $22M — CCP Equity Partners, New Enterprise Associates, Versant Ventures, Salix Ventures
- Series B, Jul 19, 2004, $15M — CCP Equity Partners, New Enterprise Associates, Versant Ventures, Salix Ventures

## Investors

- CCP Equity Partners (https://capitalatlas.ai/funds/ccp-equity-partners) — Series B, Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B, Series C
- Salix Ventures (https://capitalatlas.ai/funds/salix-ventures) — Series B, Series C